Roche’s Genentech unit bought Jecure Therapeutics and its portfolio of NLRP3 drugs in 2018, focusing on peripheral drugs for NASH, liver fibrosis, gout, inflammatory bowel disease, and ...

As Eli Lilly scores in weight loss with Tirzepatide and Madrigal and Intercept fight for clinical success in the next wave of NASH therapeutics, industry professionals are debating what’s next.

The analyst notes that Akero Therapeutics' case is similar to other ... The analyst's comments underscore the significance of Akero's NASH treatment in the context of the broader biotech industry ...